Study summary

Tirzepatide protected the heart at least as well as dulaglutide

SURPASS-CVOT trial (tirzepatide) · 13,299 people, phase 3 · Published December 2025, New England Journal of Medicine

12.2%had a heart attack, stroke or heart death, vs 13.1% with dulaglutide

What was tested

Tirzepatide against dulaglutide (a GLP-1 drug already shown to lower heart risk) in people with type 2 diabetes and heart or blood vessel disease.

What they found

What it means

Tirzepatide can be used for heart protection in type 2 diabetes.

N Engl J Med, via PubMed ↗ Trial record NCT04255433 ↗ ← Back to the outlook
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.